UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
August 2, 2007
Date of Report (Date of earliest event reported)
--------------------------------------------------------------------------------
ANTIGENICS INC.
(Exact name of registrant as specified in its charter)
--------------------------------------------------------------------------------
DELAWARE 000-29089 06-1562417
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
162 Fifth Avenue, Suite 900
New York, NY 10010
(Address of principal executive offices) (Zip Code)
212-994-8200
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On August 2, 2007, Antigenics Inc. announced that it has
completed the submission of an application for marketing
authorization with the Russian Ministry of Public Health for the
use of Oncophage(R) (vitespen) in the treatment of kidney cancer
patients at intermediate risk for disease recurrence. This
submission contains final investigator-reported results from the
largest, randomized, Phase 3 kidney cancer trial ever completed
in the adjuvant treatment setting. The full text of the press
release issued in connection with the announcement is being
furnished as Exhibit 99.1 to this current report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is furnished herewith:
99.1 Press Release dated August 2, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: August 2, 2007
By: /s/ Garo H. Armen
-------------------------
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description of Exhibit
----------- ----------------------
99.1 Press Release dated August 2, 2007